Search research articles
Contact Us
Filters
Showing results (111-120 of 184) with videos related to
Page
of 19
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2020
Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma
Laurèl Rauschenbach, Anja Wieland, Roman Reinartz, et al.
Neuro-Oncology
|
July 2, 2013
End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey
Oliver Heese, Eva Vogeler, Tobias Martens, et al.
Neuro-Oncology
|
June 19, 2026
Tumor-associated epilepsy at diagnosis in glioblastoma patients reveals an inflammatory molecular signature and is associated with better overall survival
Lilyana Dimova, Jenny Stritzelberger, Diyan Dimov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2017
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in <i>EGFR</i>-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Jörg Felsberg, Bettina Hentschel, Kerstin Kaulich, et al.
Oncology
|
September 7, 2013
FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival
Christina Schaub, Susanne Greschus, Mirko Seifert, et al.
Cancers
|
May 15, 2019
A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells
Christian Kaltschmidt, Constanze Banz-Jansen, Tahar Benhidjeb, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 25, 2015
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
Manfred Westphal, Oliver Heese, Joachim P Steinbach, et al.
The Lancet. Oncology
|
May 15, 2012
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick, Michael Platten, Christoph Meisner, et al.
Annals of Neurology
|
August 10, 2010
Residual tumor cells are unique cellular targets in glioblastoma
Martin Glas, Barbara H Rath, Matthias Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2009
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network
Michael Weller, Jörg Felsberg, Christian Hartmann, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 184) with videos related to
Sort By:
Page
of 19
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2020
Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma
Laurèl Rauschenbach, Anja Wieland, Roman Reinartz, et al.
Neuro-Oncology
|
July 2, 2013
End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey
Oliver Heese, Eva Vogeler, Tobias Martens, et al.
Neuro-Oncology
|
June 19, 2026
Tumor-associated epilepsy at diagnosis in glioblastoma patients reveals an inflammatory molecular signature and is associated with better overall survival
Lilyana Dimova, Jenny Stritzelberger, Diyan Dimov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2017
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in <i>EGFR</i>-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Jörg Felsberg, Bettina Hentschel, Kerstin Kaulich, et al.
Oncology
|
September 7, 2013
FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival
Christina Schaub, Susanne Greschus, Mirko Seifert, et al.
Cancers
|
May 15, 2019
A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells
Christian Kaltschmidt, Constanze Banz-Jansen, Tahar Benhidjeb, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 25, 2015
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
Manfred Westphal, Oliver Heese, Joachim P Steinbach, et al.
The Lancet. Oncology
|
May 15, 2012
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick, Michael Platten, Christoph Meisner, et al.
Annals of Neurology
|
August 10, 2010
Residual tumor cells are unique cellular targets in glioblastoma
Martin Glas, Barbara H Rath, Matthias Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2009
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network
Michael Weller, Jörg Felsberg, Christian Hartmann, et al.
Page
of 19